会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Isatinoxime derivatives, their preparation and use
    • 伊马替尼衍生物,其制备和用途
    • US5242918A
    • 1993-09-07
    • US936579
    • 1992-08-27
    • Frank WatjenBjarne H. DahlJorgen DrejerLeif H. Jensen
    • Frank WatjenBjarne H. DahlJorgen DrejerLeif H. Jensen
    • C07C205/45C07D471/04C07D487/04C07D491/04C07D491/048C07D495/04
    • C07D471/04C07C205/45C07D487/04C07D491/04C07D495/04
    • A compound having the formula ##STR1## wherein R.sup.4 and R.sup.5 independently are hydrogen, halogen, CF.sub.3, CN, NO.sub.2 or SO.sub.2 NR.sup.1 R.sup.2 whereinR.sup.1 is hydrogen or straight, C.sub.1-6 -alkyl which may be branched or cyclic,R.sup.2 is hydrogen or straight, C.sub.1-6 -alkyl which may be branched or cyclic,or wherein R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --, wherein A is O, S, CH.sub.2 or NR.sup.I, wherein R.sup.I is H, C.sub.1-6 -alkyl which may be straight, branched or cyclic, n is 0, 1, 2, 3, 4, 5 and m is 0, 1, 2, 3, 4, 5;Q is NOH or O;Z=O, S, N--R.sup.II, ##STR2## wherein R.sup.II, R.sup.III, R.sup.IV and R.sup.V independently are hydrogen, benzyl, C.sub.1-6 carboxylic acid-acyl, C.sub.1-6 -alkoxy which may be branched or cyclic, or C.sub.1-6 -alkyl which may be branched or cyclic;X is --(CH.sub.2).sub.o -- wherein o is 0, 1, 2, or 3;Y is --(CH.sub.2).sub.p -- wherein p is 0, 1, 2 or 3;.alpha. and .beta. indicate attachment points,and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.
    • 具有式“IMAGE”的化合物,其中R 4和R 5独立地是氢,卤素,CF 3,CN,NO 2或SO 2 NR 1 R 2,其中R 1是氢或直链,可以是支链或环状的C 1-6 - 烷基,R 2是氢或直链, 可以是支链或环状的C 1-6 - 烷基,或其中R 1和R 2一起表示 - (CH 2)nA-(CH 2)m - ,其中A是O,S,CH 2或NRI,其中R 1是H,C 1-6 - 烷基,其可以是直链,支链或环状的,n为0,1,2,3,4,5,m为0,1,2,3,4,5; Q是NOH或O; Z = O,S,N-RII,其中RII,RIII,RIV和RV独立地是氢,苄基,C1-6羧酸 - 酰基,可以是支链或环状的C1-6 - 烷氧基或C1-6 可以是支链或环状的 - 烷基; X是 - (CH 2)o - ,其中o是0,1,2或3; Y是 - (CH 2)p - ,其中p是0,1,2或3; α和β表示连接点,以及一种治疗对谷氨酸和天冬氨酸受体的封闭有反应的哺乳动物(包括人)的病症的方法。
    • 2. 发明授权
    • Isatineoxime derivatives, their preparation and use
    • 异恶嗪衍生物,其制备和用途
    • US5436250A
    • 1995-07-25
    • US088328
    • 1993-07-07
    • Frank WatjenBjarne H. DahlJorgen DrejerLein H. Jensen
    • Frank WatjenBjarne H. DahlJorgen DrejerLein H. Jensen
    • C07C205/45C07D471/04C07D487/04C07D491/04C07D491/048C07D495/04A61K31/395
    • C07C205/45C07D471/04C07D487/04C07D491/04C07D495/04
    • A compound having the formula ##STR1## wherein R.sup.4 and R.sup.5 independently are hydrogen, halogen, CF.sub.3, CN, NO.sub.2 or SO.sub.2 NR.sup.1 R.sup.2 whereinR.sup.1 is hydrogen or C.sub.1-6 -alkyl which may be straight, branched or cyclic,R.sup.2 is hydrogen or C.sub.1-6 -alkyl which may be straight, branched or cyclic, or wherein R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --, wherein A is O, S, CH.sub.2 or NR.sup.I, wherein R.sup.I is H, C.sub.1-6 -alkyl which may be straight, branched or cyclic, n is 0, 1, 2, 3, 4, 5 and m is 0, 1, 2, 3, 4, 5;R.sup.II is hydrogen, benzyl, (C.dbd.O)CF.sub.3, C.sub.1-6 -carboxylic acid acyl, C.sub.1-6 -alkoxy which may be branched or cyclic, or C.sub.1-6 -alkyl which may be straight, branched or cyclic, CH.sub.2 CO.sub.2 R.sup.VI wherein R.sup.VI is hydrogen or C.sub.1-6 -alkyl which may be straight or branched;and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.
    • 具有式“IMAGE”的化合物,其中R4和R5独立地是氢,卤素,CF3,CN,NO2或SO2NR1R2,其中R1是氢或可以是直链,支链或环状的C1-6烷基,R2是氢或C1- 其可以是直链,支链或环状的,或其中R 1和R 2一起表示 - (CH 2)n -A(CH 2)m - ,其中A是O,S,CH 2或NRI,其中R 1是H,C 1-6 - 烷基,其可以是直链,支链或环状的,n为0,1,2,3,4,5,m为0,1,2,3,4,5; RII是氢,苄基,(C = O)CF 3,C 1-6 - 羧酸酰基,可以是支链或环状的C 1-6 - 烷氧基或可以是直链,支链或环状的C 1-6 - 烷基,CH 2 CO 2 RVI,其中 RVI是氢或可以是直链或支链的C1-6烷基; 以及治疗对谷氨酸和天冬氨酸受体的阻断作用的哺乳动物(包括人)的病症的方法。
    • 6. 发明授权
    • Isatine derivatives, their preparation and use
    • 伊马替尼衍生物,其制备和用途
    • US5198461A
    • 1993-03-30
    • US710790
    • 1991-06-05
    • Frank WatjenJorgen DrejerLeif H. Jensen
    • Frank WatjenJorgen DrejerLeif H. Jensen
    • C07D209/40
    • C07D209/40
    • A method of treatment with compounds having the formula ##STR1## R.sup.1 is hydrogen, C.sub.1-6 -alkyl which may be branched, C.sub.3-7 -cycloalkyl, benzyl, phenyl which may be substituted, acyl, hydroxy, C.sub.1-6 -alkoxy, CH.sub.2 CO.sub.2 R' wherein R' is hydrogen or C.sub.1-6 -alkyl which may be branched, CH.sub.2 CN, CH.sub.2 CONR.sup.IV R.sup.V wherein R.sup.IV and R.sup.V independently are hydrogen or C.sub.1-6 -alkyl, or CH.sub.2 C(.dbd.NOH)NH.sub.2 ; R.sup.2 is hydrogen, benzyl, C.sub.1-6 -alkyl which may be branched, or C.sub.3-7 -cycloalkyl; R.sup.4, R.sup.5, R.sup.6, R.sup.7 independently are hydrogen, C.sub.1-6 -alkyl which may be branched, phenyl, halogen, C.sub.1-6 -alkoxy, NO.sub.2, CN, CF.sub.3, OCF.sub.3, or SO.sub.2 NR"R'" wherein R" and R'" independently are hydrogen, aralkoxy, aralkyl, or C.sub.1-6 -alkyl; or R.sup.6 and R.sup.7 together form an additional 4 to 7 membered ring which may be aromatic or partial saturated and which may be substituted with halogen, NO.sub.2, CF.sub.3, CN, OCF.sub.3, SO.sub.2 NR" R"' wherein R" and R"' independently are hydrogen, aralkoxy, aralkyl, or C.sub.1-6 -alkyl, and R.sup.4 and R.sup.5 have the meanings set forth above, are disclosed, as well as pharmaceutical compositions thereof. Certain of the compounds are novel.The compounds and pharmaceutical compositions containing the compounds are useful in the treatment of central nervous system disorders and especially conditions sensitive to excitatory amino acids.
    • 具有下式的化合物的方法是氢,可以是支链的C 1-6 - 烷基,C 3-7 - 环烷基,苄基,可被取代的苯基,酰基,羟基,C 1-6 - 烷氧基, CH2CO2R'其中R'是氢或可以是支链的C 1-6 - 烷基,CH 2 CN,CH 2 CONRIVRV其中RIV和RV独立地是氢或C 1-6 - 烷基或CH 2 C(= NOH)NH 2; R2是氢,苄基,可以是支链的C 1-6 - 烷基或C 3-7 - 环烷基; R4,R5,R6,R7独立地是氢,可以是支链的C1-6烷基,苯基,卤素,C1-6烷氧基,NO2,CN,CF3,OCF3或SO2NR''R“ '和R“独立地是氢,芳烷氧基,芳烷基或C 1-6 - 烷基; 或R6和R7一起形成另外的4至7元环,其可以是芳族或部分饱和的并且可以被卤素,NO 2,CF 3,CN,OCF 3,SO 2 NR“R”取代,其中R“和R' 独立地是氢,芳烷氧基,芳烷基或C 1-6 - 烷基,并且R 4和R 5具有上述含义,以及其药物组合物。 某些化合物是新颖的。 含有这些化合物的化合物和药物组合物可用于治疗中枢神经系统疾病,特别是对兴奋性氨基酸敏感的病症。
    • 7. 发明授权
    • Indole-2,3-dione-3-oxime derivatives
    • 吲哚-2,3-二酮-3-肟衍生物
    • US6124285A
    • 2000-09-26
    • US77554
    • 1998-06-01
    • Frank WatjenJorgen Drejer
    • Frank WatjenJorgen Drejer
    • A61K20060101A61K31/00A61K31/40A61K31/407A61K31/435A61K31/47A61K31/4738A61K31/4745A61K31/55A61P25/00A61P25/04A61P25/08A61P25/14A61P25/16A61P25/18A61P25/22A61P25/28A61P25/30A61P43/00C07D20060101C07D209/40C07D471/04C07D487/04A61K31/4375A61K31/5375C07D417/12
    • C07D471/04C07D487/04
    • The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising the effect of excitatory amino acids, such as glutamate. More specifically the novel indole-2,3-dione-3-oxime derivatives of the invention may be described by general formula (I), wherein R.sup.3 represents "Het", or a group of formula (II), wherein "Het" represents a saturated or unsaturated, 4 to 7 membered, monocyclic, heterocyclic ring, at least one of R.sup.31, R.sup.32, and R.sup.33 independendy represents hydrogen, alkyl, or hydroxyalkyl, and at least one of R.sup.31, R.sup.32, and R.sup.33 independently represents (CH.sub.2).sub.n R.sup.34 ; wherein R.sup.34 represents hydroxy, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, cycloalkyl-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, CONR.sup.35 R.sup.36, or "Het"; wherein n is 0, 1, 2, or 3; and R.sup.5 represents phenyl, naphthyl, thienyl, or pyridyl, all of which may be substituted. "A" represents a ring of five to seven atoms fused with the benzo ring at the positions marked "a" and "b", and formed by the following bivalent radicals: a-NR.sup.6 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --NR.sup.6 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --NR.sup.6 -b; a-NR.sup.6 --CH.sub.2 --CH.sub.2 --H.sub.2 -b; a-CH.sub.2 --NR.sup.6 --CH.sub.2 --CH.sub.2 -b; a--CH.sub.2 --CH.sub.2 --NR.sup.6 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.6 -b; a-NR.sup.6 --CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --NR.sup.6 --CH.sub.2 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --NR.sup.6 --CH.sub.2 --CH.sub.2 -b; a-CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.6 --CH.sub.2 -b; or a-CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2 --NR.sup.6 -b; wherein R.sup.6 represents hydrogen, alkyl or CH.sub.2 CH.sub.2 OH; or a pharmaceutically acceptable salt thereof.
    • PCT No.PCT / DK97 / 00418 Sec。 371日期1998年6月1日 102(e)日期1998年6月1日PCT 1997年10月1日PCT PCT。 公开号WO98 / 14447 日期:1998年4月9日本发明涉及能够拮抗兴奋性氨基酸如谷氨酸的作用的新的吲哚-2,3-二酮-3-肟衍生物。 更具体地,本发明的新的吲哚-2,3-二酮-3-肟衍生物可以由通式(I)描述,其中R 3表示“Het”,或式(II)的基团,其中“Het”表示 饱和或不饱和的4至7元单环杂环,R 31,R 32和R 33独立的至少一个表示氢,烷基或羟基烷基,并且R 31,R 32和R 33中的至少一个独立地表示(CH 2) nR34; 其中R34表示羟基,羧基,烷氧基羰基,烯氧基羰基,炔氧基羰基,环烷氧基羰基,环烷基 - 烷氧基羰基,芳氧基羰基,芳烷氧羰基,CONR35R36或“Het”。 其中n为0,1,2或3; 并且R 5表示苯基,萘基,噻吩基或吡啶基,它们都可以被取代。 “A”表示在标记为“a”和“b”的位置与苯并环稠合的5至7个原子的环,由以下二价基团形成:a-NR6-CH2-CH2-b; a-CH2-NR6-CH2-b; a-CH2-CH2-NR6-b; a-NR6-CH2-CH2-H2-b; a-CH2-NR6-CH2-CH2-b; a-CH2-CH2-NR6-CH2-b; a-CH2-CH2-CH2-NR6-b; a-NR6-CH2-CH2-CH2-CH2-b; a-CH 2 -NR 6 -CH 2 -CH 2 -CH 2 -B; a-CH2-CH2-NR6-CH2-CH2-b; a-CH2-CH2-CH2-NR6-CH2-b; 或a-CH2-CH2-CH2-CH2-NR6-b; 其中R6表示氢,烷基或CH2CH2OH; 或其药学上可接受的盐。
    • 8. 再颁专利
    • Indole-2,3-dione-3-oxime derivatives
    • 吲哚-2,3-二酮-3-肟衍生物
    • USRE38200E1
    • 2003-07-22
    • US09956892
    • 2001-09-21
    • Frank WatjenJorgen Drejer
    • Frank WatjenJorgen Drejer
    • A61K315375
    • C07D471/04C07D487/04
    • The present invention relates to novel indole-2,3-dione-3-oxime derivatives capable of antagonising the effect of excitatory amino acids, such as glutamate. More specifically the novel indole-2,3-dione-3-oxime derivatives of the invention may be described by general formula (I), wherein R3 represents “Het”, or a group of formula (II), wherein “Het” represents a saturated or unsaturated, 4 to 7 membered, monocyclic, heterocyclic ring, at least one of R31, R32, and R33 independendy represents hydrogen, alkyl, or hydroxyalkyl, and at least one of R31, R32, and R33 independently represents (CH2)nR34; wherein R34 represents hydroxy, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, cycloalkylalkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, CONR35R36, or “Het”; wherein n is 0, 1, 2, or 3; and R5 represents phenyl, naphthyl, thienyl, or pyridyl, all of which may be substituted. “A” represents a ring of five to seven atoms fused with the benzo ring at the positions marked “a” and “b”, and formed by the following bivalent radicals: a-NR6—CH2—CH2-b; a-CH2—NR6—CH2-b; a-CH2—CH2—NR6-b; a-NR6—CH2—CH2—H2-b; a-CH2—NR6—CH2—CH2-b; a—CH2—CH2—NR6—CH2-b; a-CH2—CH2—CH2—NR6-b; a-NR6—CH2—CH2—CH2—CH2-b; a-CH2—NR6—CH2—CH2—CH2-b; a-CH2—CH2—NR6—CH2—CH2-b; a-CH2—CH2—CH2—NR6—CH2-b; or a-CH2—CH2—CH2—CH2—NR6-b; wherein R6 represents hydrogen alkyl or CH2CH2OH; or a pharmaceutically acceptable salt thereof.
    • 本发明涉及能够拮抗兴奋性氨基酸如谷氨酸的作用的新的吲哚-2,3-二酮-3-肟衍生物。 更具体地,本发明的新的吲哚-2,3-二酮-3-肟衍生物可以由通式(I)描述,其中R 3表示“Het”,或式(II)的基团,其中“Het”表示 饱和或不饱和的4至7元单环杂环,R 31,R 32和R 33独立的至少一个表示氢,烷基或羟基烷基,并且R 31,R 32和R 33中的至少一个独立地表示(CH 2) nR34; 其中R34表示羟基,羧基,烷氧基羰基,烯氧基羰基,炔氧基羰基,环烷氧基羰基,环烷基烷氧基羰基,芳氧基羰基,芳烷氧羰基,CONR35R36或“Het”。 其中n为0,1,2或3; 并且R 5表示苯基,萘基,噻吩基或吡啶基,它们都可以被取代。 “A”表示在标记为“a”和“b”的位置与苯并环稠合的5至7个原子的环,由以下二价基团形成:a-NR6-CH2-CH2-b; a-CH2-NR6-CH2-b; a-CH2-CH2-NR6-b; a-NR6-CH2-CH2-H2-b; a-CH2-NR6-CH2-CH2-b; a-CH2-CH2-NR6-CH2-b; a-CH2-CH2-CH2-NR6-b; a-NR6-CH2-CH2-CH2-CH2-b; a-CH 2 -NR 6 -CH 2 -CH 2 -CH 2 -B; a-CH2-CH2-NR6-CH2-CH2-b; a-CH2&mdas